The current status of neurotensin-dopamine interactions. Issues and speculations.
Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06510.
A Y
AY
Deutch
D S
DS
Zahm
D000818:Animals; D001369:Axons / Q000378:metabolism; D001921:Brain / Q000378:metabolism*; D002540:Cerebral Cortex / Q000737:chemistry / Q000378:metabolism; D003342:Corpus Striatum / Q000378:metabolism; D004298:Dopamine / Q000737:chemistry / Q000378:metabolism*; D018492:Dopamine Antagonists; D065127:Dopamine D2 Receptor Antagonists; D004594:Electrophysiology; D015870:Gene Expression / Q000187:drug effects; D008636:Mesencephalon / Q000737:chemistry / Q000502:physiology; D009474:Neurons / Q000737:chemistry / Q000502:physiology; D009496:Neurotensin / Q000032:analysis / Q000096:biosynthesis / Q000737:chemistry / Q000378:metabolism*; D016627:Oxidopamine / Q000494:pharmacology; D017447:Receptors, Dopamine D1 / Q000037:antagonists & inhibitors / Q000378:metabolism; D017448:Receptors, Dopamine D2 / Q000378:metabolism; D018028:Receptors, Neurotensin; D017981:Receptors, Neurotransmitter / Q000737:chemistry; D012110:Reserpine / Q000494:pharmacology; D014446:Tyrosine 3-Monooxygenase / Q000737:chemistry / Q000235:genetics / Q000378:metabolism
D018492:Dopamine Antagonists; D065127:Dopamine D2 Receptor Antagonists; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D018028:Receptors, Neurotensin; D017981:Receptors, Neurotransmitter; D009496:Neurotensin; D012110:Reserpine; D016627:Oxidopamine; D014446:Tyrosine 3-Monooxygenase; D004298:Dopamine